Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 39Ovarian Neoplasms 29Multiple Myeloma 16Neoplasms 9Recurrence 8Lymphoma 8Fallopian Tube Neoplasms 8Triple Negative Breast Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Hodgkin Disease 7Carcinoma, Ovarian Epithelial 7Lymphoma, Non-Hodgkin 6Sarcoma 5Neoplasm Metastasis 5Burkitt Lymphoma 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lung Neoplasms 2Liver Neoplasms 2Leukemia 2Leiomyosarcoma 2Kidney Neoplasms 2Endometrial Neoplasms 2Disease Progression 2Vulvar Neoplasms 1Vaginal Neoplasms 1

Interventions

olaparib 1liposomal doxorubicin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ovarian Neoplasm Epithelial × liposomal doxorubicin × Clear all
NCT03509246 2020-01-14

Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

Seoul National University Hospital

Phase 2 Unknown
44 enrolled
Gynecologic

Ovarian Neoplasm Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡